|
1
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
William WN Jr and Glisson BS: Novel
strategies for the treatment of small-cell lung carcinoma. Nat Rev
Clin Oncol. 8:611–619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim YH and Mishima M: Second-line
chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev.
37:143–150. 2011. View Article : Google Scholar
|
|
4
|
Carbajal D, Casaco A, Arruzazabala L,
Gonzalez R and Tolon Z: Pharmacological study of Cymbopogon
citratus leaves. J Ethnopharmacol. 25:103–107. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Figueirinha A, Cruz MT, Francisco V, Lopes
MC and Batista MT: Anti-inflammatory activity of Cymbopogon
citratus leaf infusion in lipopolysaccharide-stimulated dendritic
cells: Contribution of the polyphenols. J Med Food. 13:681–690.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Francisco V, Figueirinha A, Neves BM,
García-Rodríguez C, Lopes MC, Cruz MT and Batista MT: Cymbopogon
citratus as source of new and safe anti-inflammatory drugs:
Bio-guided assay using lipopolysaccharide-stimulated macrophages. J
Ethnopharmacol. 133:818–827. 2011. View Article : Google Scholar
|
|
7
|
Onawunmi GO, Yisak WA and Ogunlana EO:
Antibacterial constituents in the essential oil of Cymbopogon
citratus (DC.) Stapf. J Ethnopharmacol. 12:279–286. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wannissorn B, Jarikasen S and
Soontorntanasart T: Antifungal activity of lemongrass oil and
lemongrass oil cream. Phytother Res. 10:551–554. 1996. View Article : Google Scholar
|
|
9
|
Pattnaik S, Subramanyam VR, Bapaji M and
Kole CR: Antibacterial and antifungal activity of aromatic
constituents of essential oils. Microbios. 89:39–46.
1997.PubMed/NCBI
|
|
10
|
Manosroi J, Dhumtanom P and Manosroi A:
Anti-proliferative activity of essential oil extracted from Thai
medicinal plants on KB and P388 cell lines. Cancer Lett.
235:114–120. 2006. View Article : Google Scholar
|
|
11
|
Boyland E and Mawson EH: Experiments on
the chemotherapy of cancer: The effect of aldehydes and glucosides.
Biochem J. 32:1982–1987. 1938. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaouki W, Leger DY, Liagre B, Beneytout
JL and Hmamouchi M: Citral inhibits cell proliferation and induces
apoptosis and cell cycle arrest in MCF-7 cells. Fundam Clin
Pharmacol. 23:549–556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dudai N, Weinstein Y, Krup M, Rabinski T
and Ofir R: Citral is a new inducer of caspase-3 in tumor cell
lines. Planta Med. 71:484–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barré B, Vigneron A, Perkins N, Roninson
IB, Gamelin E and Coqueret O: The STAT3 oncogene as a predictive
marker of drug resistance. Trends Mol Med. 13:4–11. 2007.
View Article : Google Scholar
|
|
16
|
Ikuta K, Takemura K, Kihara M, Nishimura
M, Ueda N, Naito S, Lee E, Shimizu E and Yamauchi A: Overexpression
of constitutive signal transducer and activator of transcription 3
mRNA in cisplatin-resistant human non-small cell lung cancer cells.
Oncol Rep. 13:217–222. 2005.PubMed/NCBI
|
|
17
|
Pfeiffer M, Hartmann TN, Leick M, Catusse
J, Schmitt-Graeff A and Burger M: Alternative implication of CXCR4
in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer.
100:1949–1956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rosen N, Bolen JB, Schwartz AM, Cohen P,
DeSeau V and Israel MA: Analysis of pp60c-src protein
kinase activity in human tumor cell lines and tissues. J Biol Chem.
261:13754–13759. 1986.PubMed/NCBI
|
|
19
|
Mazurenko NN, Kogan EA, Zborovskaya IB and
Kisseljov FL: Expression of pp60c-src in human small
cell and non-small cell lung carcinomas. Eur J Cancer. 28:372–377.
1992. View Article : Google Scholar
|
|
20
|
Mellström K, Bjelfman C, Hammerling U and
Påhlman S: Expression of c-src in cultured human neuroblastoma and
small-cell lung carcinoma cell lines correlates with neurocrine
differentiation. Mol Cell Biol. 7:4178–4184. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ueda Y, Igishi T, Hashimoto K, Suyama H,
Araki K, Sumikawa T, Takeda K, Nakazaki H, Matsunami K, Kodani M,
et al: Synergistic cell growth inhibition by the combination of
amrubicin and Akt-suppressing tyrosine kinase inhibitors in small
cell lung cancer cells: Implication of c-Src and its inhibitor. Int
J Oncol. 34:689–696. 2009.PubMed/NCBI
|
|
22
|
Roelle S, Grosse R, Buech T, Chubanov V
and Gudermann T: Essential role of Pyk2 and Src kinase activation
in neuropeptide-induced proliferation of small cell lung cancer
cells. Oncogene. 27:1737–1748. 2008. View Article : Google Scholar
|
|
23
|
Harada D, Takigawa N and Kiura K: The role
of STAT3 in non-small cell lung cancer. Cancers (Basel). 6:708–722.
2014. View Article : Google Scholar
|
|
24
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar
|
|
25
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Frank DA: STAT3 as a central mediator of
neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007.
View Article : Google Scholar
|
|
27
|
Yamaji Y, Matsubara S, Yamadori I, Sato M,
Fujita T, Fujita J and Takahara J: Characterization of a
small-cell-lung-carcinoma cell line from a patient with
cancer-associated retinopathy. Int J Cancer. 65:671–676. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ichihara N, Kubota Y, Kitanaka A, Tanaka T
and Taminato T: Inhibition of Src reduces gemcitabine-induced
cytotoxicity in human pancreatic cancer cell lines. Cancer Lett.
260:155–162. 2008. View Article : Google Scholar
|
|
29
|
Bliss CI: The toxicity of poisons applied
jointly. Ann Appl Biol. 26:585–615. 1939. View Article : Google Scholar
|
|
30
|
Foucquier J and Guedj M: Analysis of drug
combinations: Current methodological landscape. Pharmacol Res
Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bretz NP, Salnikov AV, Perne C, Keller S,
Wang X, Mierke CT, Fogel M, Erbe-Hofmann N, Schlange T, Moldenhauer
G, et al: CD24 controls Src/STAT3 activity in human tumors. Cell
Mol Life Sci. 69:3863–3879. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turkson J, Bowman T, Garcia R, Caldenhoven
E, De Groot RP and Jove R: Stat3 activation by Src induces specific
gene regulation and is required for cell transformation. Mol Cell
Biol. 18:2545–2552. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okutani Y, Kitanaka A, Tanaka T, Kamano H,
Ohnishi H, Kubota Y, Ishida T and Takahara J: Src directly
tyrosine-phosphorylates STAT5 on its activation site and is
involved in erythropoietin-induced signaling pathway. Oncogene.
20:6643–6650. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hanke JH, Gardner JP, Dow RL, Changelian
PS, Brissette WH, Weringer EJ, Pollok BA and Connelly PA: Discovery
of a novel, potent, and Src family-selective tyrosine kinase
inhibitor. Study of Lck- and FynT-dependent T cell activation. J
Biol Chem. 271:695–701. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alas S and Bonavida B: Inhibition of
constitutive STAT3 activity sensitizes resistant non-Hodgkin's
lymphoma and multiple myeloma to chemotherapeutic drug-mediated
apoptosis. Clin Cancer Res. 9:316–326. 2003.PubMed/NCBI
|
|
36
|
Duan Z, Foster R, Bell DA, Mahoney J,
Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal
transducers and activators of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim D, Cheng GZ, Lindsley CW, Yang H and
Cheng JQ: Targeting the phosphatidylinositol-3 kinase/Akt pathway
for the treatment of cancer. Curr Opin Investig Drugs. 6:1250–1258.
2005.PubMed/NCBI
|
|
38
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
39
|
Fujiwara Y, Kawada K, Takano D, Tanimura
S, Ozaki K and Kohno M: Inhibition of the PI3 kinase/Akt pathway
enhances doxorubicin-induced apoptotic cell death in tumor cells in
a p53-dependent manner. Biochem Biophys Res Commun. 340:560–566.
2006. View Article : Google Scholar
|
|
40
|
Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li
JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide
3-kinase/Akt pathway plays an important role in chemoresistance of
gastric cancer cells against etoposide and doxorubicin induced cell
death. Int J Cancer. 122:433–443. 2008. View Article : Google Scholar
|
|
41
|
Arcaro A, Aubert M, Espinosa del Hierro
ME, Khanzada UK, Angelidou S, Tetley TD, Bittermann AG, Frame MC
and Seckl MJ: Critical role for lipid raft-associated Src kinases
in activation of PI3K-Akt signalling. Cell Signal. 19:1081–1092.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Miller AA, Pang H, Hodgson L, Ramnath N,
Otterson GA, Kelley MJ, Kratzke RA and Vokes EE: Cancer and A phase
II study of dasatinib in patients with chemosensitive relapsed
small cell lung cancer (Cancer and Leukemia Group B 30602). J
Thorac Oncol. 5:380–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Molina JR, Foster NR, Reungwetwattana T,
Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J and
Adjei AA: A phase II trial of the Src-kinase inhibitor saracatinib
after four cycles of chemotherapy for patients with extensive stage
small cell lung cancer: NCCTG trial N-0621. Lung Cancer.
85:245–250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Song L, Morris M, Bagui T, Lee FY, Jove R
and Haura EB: Dasatinib (BMS-354825) selectively induces apoptosis
in lung cancer cells dependent on epidermal growth factor receptor
signaling for survival. Cancer Res. 66:5542–5548. 2006. View Article : Google Scholar : PubMed/NCBI
|
